← Eichor
Study identifier: NCT05986487 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Impact of Sleep-Disordered Breathing Management in Systemic Hypertension Control: METASLEEP Project

Condition: Hypertension · Obstructive Sleep Apnea  ·  Sponsor: Sociedad Española de Neumología y Cirugía Torácica

PhaseN/A
Planned participants1523
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Hypertension is a frequent condition affecting 11M Spanish citizens and is the leading modifiable contributor to cardiovascular disease and death. Our society has already identified balanced diet, physical activity and emotional wellbeing as the 3 pillars of healthy living. Healthy sleep should be incorporated as the fourth pillar, as clearly supported by the extensively available scientific evidence. Targeting sleep is considered the new frontier in cardiovascular prevention. In fact, recent scientific evidence encourages consideration of including sleep disturbances in the top 10 potentially modifiable cardiovascular risk factors. Sleep-disordered breathing affect 30-80% of patients with hypertension. The personalized management of hypertension is challenging due to; i) the misclassification of hypertensive patients (affecting 1 out of 3 patients); ii) the lack of adequate treatment of high mortality risk hypertensive phenotypes today is an unmet clinical need; iii) unawareness of the impact of sleep-disordered breathing as a modifiable risk factor for hypertension. Importantly, the investigators already made the seminal observations showing that the treatment for sleep-disordered breathing reduces blood pressure in the hypertensive phenotypes with the highest mortality risk. Given the need for novel strategies to treat hypertension and, supported by our data, the investigators propose to study and treat sleep-disordered breathing to improve hypertension control. METASLEEP …

This description comes directly from the study's public registry record.

Talk to the study team

Ferran Barbé Illa, MD  ·  +34 973705372  ·  febarbe.lleida.ics@gencat.cat

Manuel Sánchez de la Torre, PhD  ·  +34 973702959  ·  manuel.sanchez@udl.cat

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital Universitari Arnau de VilanovaLleida, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05986487